Optimal First Line Therapy for Metastatic Melanoma: Nivolumab and Relatlimab

Discussing the efficacy and safety of Nivolumab and Relatlimab as a superior first-line therapy option for newly diagnosed metastatic melanoma patients, with comparisons to other treatments based on key endpoints and tolerability data presented at ASCO Annual Meeting.

• Metastatic Melanoma
• Nivolumab
• Relatlimab
• First-line Therapy
• Efficacy

josette Follow

Uploaded on Jul 02, 2024 | 0 Views

Download Presentation

Please find below an Image/Link to download the presentation.

The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. Download presentation by click this link. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.

Presentation Transcript

1. Optimal First Line Therapy for Newly Diagnosed Metastatic Melanoma Patients: Nivolumab and Relatlimab Melinda Yushak, MD MPH Winship Cancer Institute Winship Cancer Institute | Emory University 1

2. Disclosure I regularly use ipi/nivo. It has an important place in certain populations of patients such as those with brain mets. Winship Cancer Institute | Emory University 2

3. Why consider Nivolumab-relatlimab over Nivolumab and Ipilimumab? Efficacy Safety Winship Cancer Institute | Emory University 3

4. Nivolumab/Relatlimab is superior to Nivolumab Tawbi et al. Oral Presentation at ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 9502. Winship Cancer Institute | Emory University 4

5. Sub group analysis Winship Cancer Institute | Emory University 5

6. If we looked at everything on a single page** Endpoints Rela/Nivo Relativity-047 Nivolumab Relativity-047 Ipi/Nivo Checkmate 067 Nivolumab CheckMate 067 Flipped Ipi/Nivo CheckMate 511 Ipi/Nivo CheckMate 511 Median follow- up (months) 25.3 25.3 77 77 18.8 18.6 ORR (95% CI) 44% 34% 58% 45% 46% 51% CR rates 18% 18% 22% 19% 15% 13.5% PD rates 31% 42% 24% 38% 34% 26% Median PFS (months) 10.2 4.6 11.5 6.9 9.9 8.9 Median OS NR 33.2 72.1 36.9 NR NR Median DOR NR NR NR NR NR NR G3-4 TRAE 22% 12% 59% 24% 33% 48% Tawbi et al. Oral Presentation at ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 9502. **Cross-trial comparisons should be interpreted with caution Wolchok et al. JCO. 2022 40(2):127-137 Lebbe et al. JCO. 2019; 37:867-875 Winship Cancer Institute | Emory University 6

7. Nivolumab and Relatlimab is better tolerated Tawbi et al. Oral Presentation at ASCO Annual Meeting; June 2-6, 2023; Chicago, IL. Abstract 9502. CheckMate-067 Ipilimumab-Nivolumab Nivolumab Any grade Grade 3 or 4 Any grade Grade 3 or 4 Treatment-related adverse event 300 (96) 186 (59) 271 (87) 74 (24) Led to discontinuation of treatment 131 (42) 96 (31) 43 (14) 25 (8) Wolchok et al. JCO. 2022 40(2):127-137 Winship Cancer Institute | Emory University 7

8. Nivolumab and Relatlimab should be used in the first line setting Improved PFS over nivolumab Tolerable safety profile Winship Cancer Institute | Emory University 8